Ray of hope! AYUSH 64 effective in treating mild to moderate COVID-19 infection; AYUSH Ministry
30 Apr 2021 10:25:30
New Delhi, April 30: In a breakthrough in countries fight against the COVID 19, scientists have found that ayurvedic medicine AYUSH 64 is useful in the treatment of asymptomatic, mild, and moderate COVID-19 infection as an adjunct to standard care. The medicine is developed by the Central Council for Research in Ayurvedic Sciences.
According to the ministry of Ayush, Ayurvedic medicine has emerged as a ray of hope for patients with mild and moderate COVID-19 infection. It is worthwhile to mention that, initially the drug was developed for Malaria in the year 1980 and now is repurposed for COVID-19.
Ministry of AYUSH - Council of Scientific and Industrial Research (CSIR) collaboration has recently completed a robust multi-center clinical trial to evaluate the safety and efficacy of AYUSH 64 in the management of mild to moderate COVID-19 patients. The trial was conducted at three centers. KGMU, Lucknow; DMIMS, Wardha and BMC COVID Centre, Mumbai involving 70 participants in each arm.
It is a combination of 4 Ayurvedic products: Alstonia scholaris (aqueous bark extract), Picrorhiza kurroa (aqueous rhizome extract), Swertia chirata (aqueous extract of the whole plant), and Caesalpinia crista (fine-powdered seed pulp). This medicine is also recommended in National Clinical Management Protocol based on Ayurveda and Yoga which is vetted by the National Task Force on COVID-19 Management of ICMR.
Dr. Chopra, Director, Centre for Rheumatic Diseases, Pune stated that AYUSH 64 as an adjunct to standard of care (SoC) showed significant improvement and thus lesser period of hospitalization as compared to SoC alone. He also shared that several significant beneficial effects of AYUSH 64 on general health, fatigue, anxiety, stress, appetite, general happiness, and sleep were also observed.
He concluded by saying that this controlled drug trial study has provided substantial evidence that AYUSH 64 can be effectively and safely used to treat mild to moderate cases of COVID-19 as adjuvant to SoC.
.
.